Roles of partitioning-defective protein 6 (Par6) and its complexes in the proliferation, migration and invasion of cancer cells
© 2017 John Wiley & Sons Australia, Ltd..
A pivotal regulator of cell polarity and homeostasis, partitioning-defective protein 6 (Par6) forms multicomponent complexes that not only regulate cell polarity and stabilize cell morphology, but have also been demonstrated to participate in the proliferation, migration and invasion of cancer cells. The transforming growth factor (TGF)-β and extracellular signal-regulated kinase (Erk) 1/2 pathways are the most thoroughly studied pathways involving Par6 in many cancers. Aurothiomalate has been used to disrupt the interaction between Par6 and atypical protein kinase C within the multicomponent complexes, and has been shown to effectively block transformed growth and metastasis in vitro and/or in vivo in a variety of cancers, including pancreatic, prostate and lung cancers, as well as alveolar rhabdomyosarcoma. It is likely that with further revelations regarding the critical roles of Par6 in cancer initiation, progression and metastasis, targeted therapies against Par6 will be discovered and prove effective preclinically, and hopefully clinically, in cancer treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Clinical and experimental pharmacology & physiology - 44(2017), 9 vom: 07. Sept., Seite 909-913 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruan, Lingling [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.04.2018 Date Revised 04.04.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/1440-1681.12794 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM272704725 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM272704725 | ||
| 003 | DE-627 | ||
| 005 | 20231224235440.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1440-1681.12794 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0909.xml |
| 035 | |a (DE-627)NLM272704725 | ||
| 035 | |a (NLM)28590507 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruan, Lingling |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Roles of partitioning-defective protein 6 (Par6) and its complexes in the proliferation, migration and invasion of cancer cells |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.04.2018 | ||
| 500 | |a Date Revised 04.04.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 John Wiley & Sons Australia, Ltd. | ||
| 520 | |a A pivotal regulator of cell polarity and homeostasis, partitioning-defective protein 6 (Par6) forms multicomponent complexes that not only regulate cell polarity and stabilize cell morphology, but have also been demonstrated to participate in the proliferation, migration and invasion of cancer cells. The transforming growth factor (TGF)-β and extracellular signal-regulated kinase (Erk) 1/2 pathways are the most thoroughly studied pathways involving Par6 in many cancers. Aurothiomalate has been used to disrupt the interaction between Par6 and atypical protein kinase C within the multicomponent complexes, and has been shown to effectively block transformed growth and metastasis in vitro and/or in vivo in a variety of cancers, including pancreatic, prostate and lung cancers, as well as alveolar rhabdomyosarcoma. It is likely that with further revelations regarding the critical roles of Par6 in cancer initiation, progression and metastasis, targeted therapies against Par6 will be discovered and prove effective preclinically, and hopefully clinically, in cancer treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a cell polarization | |
| 650 | 4 | |a epithelial-mesenchymal transition | |
| 650 | 4 | |a partitioning-defective protein 6 | |
| 650 | 4 | |a transforming growth factor beta | |
| 650 | 7 | |a Adaptor Proteins, Signal Transducing |2 NLM | |
| 650 | 7 | |a PARD6A protein, human |2 NLM | |
| 700 | 1 | |a Shen, Yanting |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Ziwen |e verfasserin |4 aut | |
| 700 | 1 | |a Shang, Dongsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Zhicong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yongjin |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Yanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yafei |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Zhigang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hanqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and experimental pharmacology & physiology |d 1974 |g 44(2017), 9 vom: 07. Sept., Seite 909-913 |w (DE-627)NLM000108138 |x 1440-1681 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2017 |g number:9 |g day:07 |g month:09 |g pages:909-913 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1440-1681.12794 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2017 |e 9 |b 07 |c 09 |h 909-913 | ||